Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Company Overview - Maze Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule precision medicines for renal, cardiovascular, metabolic diseases, and obesity [5] - As of February 14, 2026, the company's stock price is $46.01, with a market capitalization of $2.21 billion and a net loss of $101.46 million over the trailing twelve months [4] Stock Performance - The stock has experienced a remarkable 284.06% price change over the past year, with a significant gain of 158% in 2025 following its IPO on January 31, 2025 [4][7] - After its IPO, Maze Therapeutics has shown consistent growth, achieving nine consecutive months of gains [7] Recent Insider Transaction - On February 2, 2026, Harold Bernstein, the Chief Medical Officer, exercised 15,000 stock options and sold the resulting shares for approximately $690,300, fully divesting his direct ownership [2][6] - This transaction was part of a 10b5-1 trading plan, which allows insiders to prearrange share transactions, and Bernstein still holds nearly 300,000 stock options post-transaction [6] Market Sentiment - Despite the recent insider sale, analysts on Wall Street consider Maze Therapeutics a strong buy, and the company continues to advance in clinical trials for multiple medicines [9]